FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy SVRA?
Source: seekingalpha
- FDA Review Progress: The U.S. FDA will review Savara's resubmitted BLA for Molbreevi (molgramostim inhalation solution) with priority status, expected to make a decision by August 22, which accelerates the drug's market entry for treating rare lung diseases.
- Drug Background: Molbreevi is a recombinant human granulocyte-macrophage colony-stimulating factor targeting autoimmune pulmonary alveolar proteinosis, and if approved, it will provide a new treatment option for patients, filling a significant market gap.
- International Application Plans: Savara intends to submit applications to the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency by the end of Q1, demonstrating its strategic intent for global market expansion and enhancing its competitiveness internationally.
- Market Reaction: Savara's shares rose approximately 4.5% in after-hours trading on Friday, reflecting investor optimism regarding the FDA's priority review, which may indicate a positive outlook for the drug's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SVRA
Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.970
Low
9.00
Averages
10.17
High
11.00
Current: 5.970
Low
9.00
Averages
10.17
High
11.00
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Savara Seeks FDA Approval for Molbreevi to Treat Rare Lung Disease
- FDA Approval Progress: Savara Inc. has submitted an application for its experimental therapy Molbreevi, with the FDA expected to decide by August 22, 2026, indicating the drug's potential in treating autoimmune pulmonary alveolar proteinosis and possibly significantly improving patient quality of life.
- Fast Track Designation: Molbreevi has received FDA's fast track, breakthrough therapy, and orphan drug designations, which not only expedite the approval process but also enhance investor confidence in the drug's market prospects, leading to a more than 3% rise in Savara's stock in after-hours trading.
- International Application Plans: Savara plans to submit applications to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, demonstrating the company's strategic intent to promote Molbreevi globally and expand market opportunities.
- Market Sentiment Shift: Retail sentiment around SVRA on Stocktwits has shifted from 'neutral' to 'bullish' over the past 24 hours, with message volume remaining high, reflecting investor optimism about the drug, as SVRA stock has more than doubled in the past 12 months, indicating strong market performance.
See More
FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
- FDA Review Progress: The U.S. FDA will review Savara's resubmitted BLA for Molbreevi (molgramostim inhalation solution) with priority status, expected to make a decision by August 22, which accelerates the drug's market entry for treating rare lung diseases.
- Drug Background: Molbreevi is a recombinant human granulocyte-macrophage colony-stimulating factor targeting autoimmune pulmonary alveolar proteinosis, and if approved, it will provide a new treatment option for patients, filling a significant market gap.
- International Application Plans: Savara intends to submit applications to the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency by the end of Q1, demonstrating its strategic intent for global market expansion and enhancing its competitiveness internationally.
- Market Reaction: Savara's shares rose approximately 4.5% in after-hours trading on Friday, reflecting investor optimism regarding the FDA's priority review, which may indicate a positive outlook for the drug's future prospects.
See More
Savara Receives FDA Priority Review for MOLBREEVI BLA Submission
- FDA Priority Review: Savara announced that the FDA has filed for Priority Review of the BLA for MOLBREEVI, with a PDUFA action date set for August 22, 2026, marking a significant milestone in the treatment of autoimmune pulmonary alveolar proteinosis and potentially offering new options for patients.
- Clinical Data Support: CEO Matt Pauls stated that the substantial data in the application demonstrates that MOLBREEVI improves pulmonary gas transfer and quality of life, which not only enhances the company's reputation in the biopharmaceutical sector but also may drive growth in its market share.
- Multiple Drug Designations: In addition to Priority Review, MOLBREEVI has received Orphan Drug Designation from both the FDA and EMA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA, indicating the drug's potential in treating rare diseases and further strengthening Savara's competitive position.
- Strategic Implications: The development of MOLBREEVI is not only Savara's lead program but could also become the first approved therapy for autoimmune PAP in the U.S. and Europe, with successful commercialization significantly enhancing the company's revenue potential and industry standing.
See More
Savara Receives Priority Review for MOLBREEVI, Potential First Therapy for Autoimmune PAP
- Priority Review Granted: The FDA has granted Priority Review for Savara's MOLBREEVI application, with a PDUFA action date set for August 22, 2026, marking a significant milestone for the company in the autoimmune PAP treatment space, which could greatly enhance patient quality of life if approved.
- European Application Plans: Savara plans to submit Marketing Authorization Applications (MAAs) for MOLBREEVI to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further expanding its international market presence and potentially generating new revenue streams.
- Unique Treatment Potential: MOLBREEVI is poised to become the first approved therapy for autoimmune PAP in both the U.S. and Europe, filling a critical market gap and addressing the urgent need for effective treatments, thereby enhancing Savara's competitive position in the biopharmaceutical industry.
- Clinical Data Support: Savara asserts that the application includes a substantial body of data demonstrating MOLBREEVI's ability to improve pulmonary gas transfer and clinical symptoms, which not only bolsters FDA confidence but also lays a solid foundation for future market promotion.
See More
Savara Secures $150M Non-Dilutive Capital for MOLBREEVI Launch
- Loan Agreement Amendment: Savara amended its loan agreement with Hercules Capital to access an additional $75 million upon FDA approval of MOLBREEVI, thereby strengthening its liquidity and financial stability.
- Increased Capital Availability: With the addition of the $75 million royalty financing, Savara will have approximately $150 million in non-dilutive capital to support the launch of MOLBREEVI, ensuring a competitive edge in the biopharmaceutical market.
- Market Potential Assessment: A U.S. claims analysis by Savara revealed that the autoimmune pulmonary alveolar proteinosis market is 50% larger than previously estimated, providing a robust foundation for MOLBREEVI's commercialization and expected sales growth.
- Regulatory Application Progress: Savara resubmitted the Biologics License Application for MOLBREEVI in December 2025, and if granted Priority Review, FDA approval could be achieved by Q3 2026, further accelerating the product launch timeline.
See More
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Savara, Inc. (NASDAQ:SVRA) to determine if the board breached fiduciary duties, particularly in light of a class action complaint filed on September 8, 2025.
- Significant Shareholder Losses: On May 27, 2025, Savara announced that its MOLBREEVI Biologics License Application was rejected by the FDA, causing a stock price drop of $0.90, or 31.69%, closing at $1.94, resulting in substantial losses for long-term shareholders.
- Insufficient Disclosure: The complaint alleges that during the class period, Savara failed to disclose critical information regarding the MOLBREEVI BLA, leading to the FDA's unlikely approval in its current form, which adversely affected the company's capital raising plans.
- Next Steps Recommended: Bragar Eagel & Squire encourages long-term shareholders of Savara to contact them to discuss legal rights and potential claims, highlighting the firm's commitment to protecting investor interests.
See More
Savara Seeks FDA Approval for Molbreevi to Treat Rare Lung Disease
- FDA Approval Progress: Savara Inc. has submitted an application for its experimental therapy Molbreevi, with the FDA expected to decide by August 22, 2026, indicating the drug's potential in treating autoimmune pulmonary alveolar proteinosis and possibly significantly improving patient quality of life.
- Fast Track Designation: Molbreevi has received FDA's fast track, breakthrough therapy, and orphan drug designations, which not only expedite the approval process but also enhance investor confidence in the drug's market prospects, leading to a more than 3% rise in Savara's stock in after-hours trading.
- International Application Plans: Savara plans to submit applications to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, demonstrating the company's strategic intent to promote Molbreevi globally and expand market opportunities.
- Market Sentiment Shift: Retail sentiment around SVRA on Stocktwits has shifted from 'neutral' to 'bullish' over the past 24 hours, with message volume remaining high, reflecting investor optimism about the drug, as SVRA stock has more than doubled in the past 12 months, indicating strong market performance.
See More
FDA Grants Priority Review for Savara's Molbreevi BLA Resubmission
- FDA Review Progress: The U.S. FDA will review Savara's resubmitted BLA for Molbreevi (molgramostim inhalation solution) with priority status, expected to make a decision by August 22, which accelerates the drug's market entry for treating rare lung diseases.
- Drug Background: Molbreevi is a recombinant human granulocyte-macrophage colony-stimulating factor targeting autoimmune pulmonary alveolar proteinosis, and if approved, it will provide a new treatment option for patients, filling a significant market gap.
- International Application Plans: Savara intends to submit applications to the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency by the end of Q1, demonstrating its strategic intent for global market expansion and enhancing its competitiveness internationally.
- Market Reaction: Savara's shares rose approximately 4.5% in after-hours trading on Friday, reflecting investor optimism regarding the FDA's priority review, which may indicate a positive outlook for the drug's future prospects.
See More
Savara Receives FDA Priority Review for MOLBREEVI BLA Submission
- FDA Priority Review: Savara announced that the FDA has filed for Priority Review of the BLA for MOLBREEVI, with a PDUFA action date set for August 22, 2026, marking a significant milestone in the treatment of autoimmune pulmonary alveolar proteinosis and potentially offering new options for patients.
- Clinical Data Support: CEO Matt Pauls stated that the substantial data in the application demonstrates that MOLBREEVI improves pulmonary gas transfer and quality of life, which not only enhances the company's reputation in the biopharmaceutical sector but also may drive growth in its market share.
- Multiple Drug Designations: In addition to Priority Review, MOLBREEVI has received Orphan Drug Designation from both the FDA and EMA, as well as Innovation Passport and Promising Innovative Medicine designations from the UK's MHRA, indicating the drug's potential in treating rare diseases and further strengthening Savara's competitive position.
- Strategic Implications: The development of MOLBREEVI is not only Savara's lead program but could also become the first approved therapy for autoimmune PAP in the U.S. and Europe, with successful commercialization significantly enhancing the company's revenue potential and industry standing.
See More
Savara Receives Priority Review for MOLBREEVI, Potential First Therapy for Autoimmune PAP
- Priority Review Granted: The FDA has granted Priority Review for Savara's MOLBREEVI application, with a PDUFA action date set for August 22, 2026, marking a significant milestone for the company in the autoimmune PAP treatment space, which could greatly enhance patient quality of life if approved.
- European Application Plans: Savara plans to submit Marketing Authorization Applications (MAAs) for MOLBREEVI to the European Medicines Agency (EMA) and the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further expanding its international market presence and potentially generating new revenue streams.
- Unique Treatment Potential: MOLBREEVI is poised to become the first approved therapy for autoimmune PAP in both the U.S. and Europe, filling a critical market gap and addressing the urgent need for effective treatments, thereby enhancing Savara's competitive position in the biopharmaceutical industry.
- Clinical Data Support: Savara asserts that the application includes a substantial body of data demonstrating MOLBREEVI's ability to improve pulmonary gas transfer and clinical symptoms, which not only bolsters FDA confidence but also lays a solid foundation for future market promotion.
See More
Savara Secures $150M Non-Dilutive Capital for MOLBREEVI Launch
- Loan Agreement Amendment: Savara amended its loan agreement with Hercules Capital to access an additional $75 million upon FDA approval of MOLBREEVI, thereby strengthening its liquidity and financial stability.
- Increased Capital Availability: With the addition of the $75 million royalty financing, Savara will have approximately $150 million in non-dilutive capital to support the launch of MOLBREEVI, ensuring a competitive edge in the biopharmaceutical market.
- Market Potential Assessment: A U.S. claims analysis by Savara revealed that the autoimmune pulmonary alveolar proteinosis market is 50% larger than previously estimated, providing a robust foundation for MOLBREEVI's commercialization and expected sales growth.
- Regulatory Application Progress: Savara resubmitted the Biologics License Application for MOLBREEVI in December 2025, and if granted Priority Review, FDA approval could be achieved by Q3 2026, further accelerating the product launch timeline.
See More
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Savara, Inc. (NASDAQ:SVRA) to determine if the board breached fiduciary duties, particularly in light of a class action complaint filed on September 8, 2025.
- Significant Shareholder Losses: On May 27, 2025, Savara announced that its MOLBREEVI Biologics License Application was rejected by the FDA, causing a stock price drop of $0.90, or 31.69%, closing at $1.94, resulting in substantial losses for long-term shareholders.
- Insufficient Disclosure: The complaint alleges that during the class period, Savara failed to disclose critical information regarding the MOLBREEVI BLA, leading to the FDA's unlikely approval in its current form, which adversely affected the company's capital raising plans.
- Next Steps Recommended: Bragar Eagel & Squire encourages long-term shareholders of Savara to contact them to discuss legal rights and potential claims, highlighting the firm's commitment to protecting investor interests.
See More
